Simplify Asset Management Inc. Sells 17,010 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Simplify Asset Management Inc. decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 52.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,338 shares of the medical equipment provider’s stock after selling 17,010 shares during the quarter. Intuitive Surgical accounts for about 0.5% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 16th biggest position. Simplify Asset Management Inc.’s holdings in Intuitive Surgical were worth $6,823,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Ridgewood Investments LLC bought a new stake in shares of Intuitive Surgical during the second quarter worth $26,000. Creekmur Asset Management LLC boosted its position in Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares during the period. LGT Financial Advisors LLC grew its stake in Intuitive Surgical by 415.4% in the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 54 shares in the last quarter. Delos Wealth Advisors LLC raised its stake in shares of Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Finally, LRI Investments LLC bought a new position in Intuitive Surgical in the first quarter worth approximately $30,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $490.01 on Friday. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18. The company has a market cap of $173.81 billion, a PE ratio of 88.45, a P/E/G ratio of 5.41 and a beta of 1.39. The business has a 50-day simple moving average of $467.17 and a two-hundred day simple moving average of $424.26.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.18 EPS. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares of the company’s stock, valued at approximately $145,113.45. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Mark Brosius sold 2,115 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the sale, the insider now directly owns 295 shares of the company’s stock, valued at approximately $145,113.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock valued at $25,528,753 in the last ninety days. Company insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ISRG. Barclays lifted their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Piper Sandler raised their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. BTIG Research upped their price target on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Stifel Nicolaus lifted their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Finally, Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their target price for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.